These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 10653004)

  • 1. Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas.
    Fujisawa H; Reis RM; Nakamura M; Colella S; Yonekawa Y; Kleihues P; Ohgaki H
    Lab Invest; 2000 Jan; 80(1):65-72. PubMed ID: 10653004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of heterozygosity on chromosome 19 in secondary glioblastomas.
    Nakamura M; Yang F; Fujisawa H; Yonekawa Y; Kleihues P; Ohgaki H
    J Neuropathol Exp Neurol; 2000 Jun; 59(6):539-43. PubMed ID: 10850866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter.
    Fujisawa H; Kurrer M; Reis RM; Yonekawa Y; Kleihues P; Ohgaki H
    Am J Pathol; 1999 Aug; 155(2):387-94. PubMed ID: 10433932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas.
    Tohma Y; Gratas C; Biernat W; Peraud A; Fukuda M; Yonekawa Y; Kleihues P; Ohgaki H
    J Neuropathol Exp Neurol; 1998 Jul; 57(7):684-9. PubMed ID: 9690672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q.
    Boström J; Cobbers JM; Wolter M; Tabatabai G; Weber RG; Lichter P; Collins VP; Reifenberger G
    Cancer Res; 1998 Jan; 58(1):29-33. PubMed ID: 9426052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular genetic alterations in glioblastomas with oligodendroglial component.
    Kraus JA; Lamszus K; Glesmann N; Beck M; Wolter M; Sabel M; Krex D; Klockgether T; Reifenberger G; Schlegel U
    Acta Neuropathol; 2001 Apr; 101(4):311-20. PubMed ID: 11355302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic pathways to primary and secondary glioblastoma.
    Ohgaki H; Kleihues P
    Am J Pathol; 2007 May; 170(5):1445-53. PubMed ID: 17456751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.
    Ohgaki H; Kleihues P
    J Neuropathol Exp Neurol; 2005 Jun; 64(6):479-89. PubMed ID: 15977639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic pathways to glioblastoma: a population-based study.
    Ohgaki H; Dessen P; Jourde B; Horstmann S; Nishikawa T; Di Patre PL; Burkhard C; Schüler D; Probst-Hensch NM; Maiorka PC; Baeza N; Pisani P; Yonekawa Y; Yasargil MG; Lütolf UM; Kleihues P
    Cancer Res; 2004 Oct; 64(19):6892-9. PubMed ID: 15466178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas.
    Nakamura M; Ishida E; Shimada K; Kishi M; Nakase H; Sakaki T; Konishi N
    Lab Invest; 2005 Feb; 85(2):165-75. PubMed ID: 15592495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of heterozygosity on chromosome 10q associated with malignancy and prognosis in astrocytic tumors, and discovery of novel loss regions.
    Daido S; Takao S; Tamiya T; Ono Y; Terada K; Ito S; Ouchida M; Date I; Ohmoto T; Shimizu K
    Oncol Rep; 2004 Oct; 12(4):789-95. PubMed ID: 15375501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic pathways to glioblastomas.
    Ohgaki H
    Neuropathology; 2005 Mar; 25(1):1-7. PubMed ID: 15822813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular pathogenesis of malignant gliomas.
    Rasheed BK; Wiltshire RN; Bigner SH; Bigner DD
    Curr Opin Oncol; 1999 May; 11(3):162-7. PubMed ID: 10328589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular pathogenesis of pediatric astrocytic tumors.
    Nakamura M; Shimada K; Ishida E; Higuchi T; Nakase H; Sakaki T; Konishi N
    Neuro Oncol; 2007 Apr; 9(2):113-23. PubMed ID: 17327574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary and secondary glioblastomas: from concept to clinical diagnosis.
    Kleihues P; Ohgaki H
    Neuro Oncol; 1999 Jan; 1(1):44-51. PubMed ID: 11550301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic mutations of PTEN in glioblastoma multiforme.
    Wang SI; Puc J; Li J; Bruce JN; Cairns P; Sidransky D; Parsons R
    Cancer Res; 1997 Oct; 57(19):4183-6. PubMed ID: 9331071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LOH on 10p14-p15 targets the PFKFB3 gene locus in human glioblastomas.
    Fleischer M; Kessler R; Klammer A; Warnke JP; Eschrich K
    Genes Chromosomes Cancer; 2011 Dec; 50(12):1010-20. PubMed ID: 21987444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors.
    Lang FF; Miller DC; Koslow M; Newcomb EW
    J Neurosurg; 1994 Sep; 81(3):427-36. PubMed ID: 8057151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation among pathology, genotype, and patient outcomes in glioblastoma.
    Homma T; Fukushima T; Vaccarella S; Yonekawa Y; Di Patre PL; Franceschi S; Ohgaki H
    J Neuropathol Exp Neurol; 2006 Sep; 65(9):846-54. PubMed ID: 16957578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent LOH at chromosome 12q22-23 and Apaf-1 inactivation in glioblastoma.
    Watanabe T; Hirota Y; Arakawa Y; Fujisawa H; Tachibana O; Hasegawa M; Yamashita J; Hayashi Y
    Brain Pathol; 2003 Oct; 13(4):431-9. PubMed ID: 14655749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.